Item 8.01                      Other Events.

On January 21, 2020, Supernus Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (FDA) has found the New Drug Application for SPN-812 for the treatment of children and adolescents with attention deficit hyperactivity disorder acceptable for review. The FDA has assigned a Prescription Drug User Fee Act target action date of November 8, 2020. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.




Item 9.01                     Financial Statements and Exhibits.

(d)                Exhibits


The following document is furnished as an Exhibit pursuant to Item 8.01 hereof:

Exhibit 99.1 - Press Release Dated January 21, 2020 .

Exhibit 104 - The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.





                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses